Study: gut hormones' regulation of fat production abnormal in obesity, fatty liver disease

November 24, 2020

CHAMPAIGN, Ill. -- Gut hormones play an important role in regulating fat production in the body. One key hormone, released a few hours after eating, turns off fat production by regulating gene expression in the liver, but this regulation is abnormal in obesity, researchers at the University of Illinois Urbana-Champaign found in a new study.

The study, led by molecular and integrative physiology professor Jongsook Kim Kemper and research scientist Young-Chae Kim, was published in the journal Nature Communications.

After eating, the pancreas produces insulin, which triggers the liver to convert digested foods into fat for storage in a process known as lipogenesis. A few hours later, when the body begins the transition to fasting mode, the liver slows fat production. While the insulin pathway has been thoroughly studied, the pathway by which lipogenesis is turned off has largely remained unknown, Kemper said.

In the new study, Kemper's team found that the gut hormone FGF15 in mice and its human counterpart FGF19 turn off fat-producing genes in the liver. The hormones are released a few hours after eating, when the body transitions from feeding to fasting. FGF15/19 activate regulatory molecules to enter the nucleus, the center of the cell where DNA is stored, and inhibit gene expression.

"This gut hormone actually acts as a breaker of insulin action, and specifically inhibits lipogenesis in the liver so that it's tightly regulated," Kemper said. "For example, with the holidays coming up, if you eat some cookies, the body will release insulin, which promotes lipogenesis. If lipogenesis is not reduced later when the body enters the fasting state, excess fat will accumulate in the liver, so the FGF19 hormone puts the brakes on fat production."

Furthermore, in experiments involving mice with obesity and human patients with nonalcoholic fatty liver disease, the researchers found that the pathway for turning off fat production was dysregulated. The genes that the gut hormone regulates were highly active, the FGF15/19-activated regulatory molecules did not even enter the cell's nucleus and the suppression markers were not added to the genes.

"This study could be very important for understanding this pathway and investigating how it is abnormal in obesity and nonalcoholic fatty liver disease," Kemper said. "It adds to our understanding of obesity, nonalcoholic fatty liver disease and other metabolic disorders. It also could have implications for other diseases such as diabetes or certain cancers, for which obesity is a risk factor.

"Based on this study, we potentially could search for therapeutic treatment options to target this pathway and increase regulatory function."
-end-
Editor's note:
To contact Jongsook Kim Kemper,
call 217-333-6317;
email jongsook@illinois.edu.

The paper "Intestinal FGF15/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A" is available online).
DOI: 10.1038/s41467-020-19803-9

University of Illinois at Urbana-Champaign, News Bureau

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.